Market Place
Sourcing Support
Health Canada OK EMPAVELI for C3G Glomerulopathy, Primary IC-MPGN
09 Apr 2026 //
GLOBENEWSWIRE
EMA Validates Tryngolza For Severe Hypertriglyceridemia
30 Mar 2026 //
PR NEWSWIRE
Emapalumab`s EMBRACE Phase 2A Results In Interferon-Gamma Sepsis
19 Mar 2026 //
PHARMIWEB
Sobi Gets EU Approval For Aspaveli In C3G And Primary IC-MPGN
16 Jan 2026 //
PR NEWSWIRE
Sobi Gets CHMP Nod For Aspaveli In C3G And Primary IC-MPGN
12 Dec 2025 //
PR NEWSWIRE
Sobi Highlights Haematology Commitment At ASH 2025
05 Dec 2025 //
PR NEWSWIRE
VALIANT Pharma Reports Positive Phase 3 Results
04 Dec 2025 //
PHARMIWEB
Sobi Presents Latest Data On Rare Inflammatory Conditions At ACR
24 Oct 2025 //
PR NEWSWIRE
Sobi Choose Kinaxis To Expedite Access To Life-Changing Treatment
02 Oct 2025 //
BUSINESSWIRE
Sobi Tops Roche in Rare Disease Patients` Reputation Rankings
23 Sep 2025 //
FIERCE PHARMA
Tryngolza (Olezarsen) Approved in EU for Chylomicronemia Syndrome
19 Sep 2025 //
PR NEWSWIRE
FDA Approves Sobi`s NASP Biologics License for Uncontrolled Gout
10 Sep 2025 //
PR NEWSWIRE
FDA Approves Doptelet for Pediatric ITP: Sobi
25 Jul 2025 //
GLOBENEWSWIRE
Apellis to Get $300M from Royalty Deal with Sobi for Aspaveli
01 Jul 2025 //
GLOBENEWSWIRE
Sobi Modifies Apellis Agreement for Aspaveli`s Ex-U.S. Royalties
01 Jul 2025 //
PR NEWSWIRE
FDA Approves Gamifant for MAS in Still’s Disease Patients
27 Jun 2025 //
PR NEWSWIRE
Sobi shares new clinical data on hematologic diseases at EHA 2025
12 Jun 2025 //
PR NEWSWIRE
Apellis, Sobi Report Ph3 Data For EMPAVELI In C3G, IC-MPGN
06 Jun 2025 //
GLOBENEWSWIRE
Sobi to share new clinical data and research at EULAR 2025
28 May 2025 //
PR NEWSWIRE
Swedish Orphan Biovitrum AB Annual General Meeting Notice
01 Apr 2025 //
PR NEWSWIRE
Sobi publishes Annual and sustainability report for 2024
31 Mar 2025 //
PR NEWSWIRE
Invitation: Sobi`s Q3 2024 report
09 Oct 2024 //
PR NEWSWIRE
Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)
29 Sep 2023 //
PR NEWSWIRE
Bulletin from Swedish Orphan Biovitrum (Sobi)`s EGM
15 Aug 2023 //
PR NEWSWIRE
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
18 Jul 2023 //
PR NEWSWIRE
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
30 Jun 2023 //
PR NEWSWIRE
Bulletin from Swedish Orphan Biovitrum (Sobi)`s Annual General Meeting (AGM)
09 May 2023 //
PR NEWSWIRE
Sobi`s high-priority rare disease drug runs into a wall at EMA
24 Jul 2020 //
ENDPTS
FDA approves Sobi’s Gamifant for rare, fatal childhood disease
23 Nov 2018 //
PHARMAPHORUM
Teva successfully used a rare pediatric PRV to speed the approval for Ajovy
21 Nov 2018 //
RAPS
Sobi’s $50M bet on a rare disease drug pays off with a quick FDA nod
20 Nov 2018 //
ENDPTS
Sobi signs $450M deal for rare disease drug emapalumab, boosting I/O pipeline
21 Jul 2018 //
ENDPTS
Swedish Orphan Biovitrum AB - Orfadin Capsules Approved in the Kingdom of Saudi Arabia
16 May 2017 //
PR NEWSWIRE
Dipharma announces the validation of disanit® (nitisinone) marketing authorization application in Europe
23 Feb 2017 //
PRESS RELEASE
Sobi™ Enters Into new Distribution Agreement With Valeant for Ammonul®
21 Feb 2017 //
PR NEWSWIRE
Sobi Obtains Approval From the European Commission for new Dosing Frequency
02 Feb 2017 //
FINANCE YAHOO
